Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.

Liu R, Mendez-Rios JD, Peng C, Xiao W, Weisberg AS, Wyatt LS, Moss B.

PLoS Pathog. 2019 May 30;15(5):e1007710. doi: 10.1371/journal.ppat.1007710. eCollection 2019 May.

2.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.

Jones AT, Shen X, Walter KL, LaBranche CC, Wyatt LS, Tomaras GD, Montefiori DC, Moss B, Barouch DH, Clements JD, Kozlowski PA, Varadarajan R, Amara RR.

Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4.

3.

Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses.

Chea LS, Wyatt LS, Gangadhara S, Moss B, Amara RR.

J Virol. 2019 Feb 19;93(5). pii: e01648-18. doi: 10.1128/JVI.01648-18. Print 2019 Mar 1.

PMID:
30541829
4.

RNA Polymerase Mutations Selected during Experimental Evolution Enhance Replication of a Hybrid Vaccinia Virus with an Intermediate Transcription Factor Subunit Replaced by the Myxoma Virus Ortholog.

Stuart CA, Zhivkoplias EK, Senkevich TG, Wyatt LS, Moss B.

J Virol. 2018 Sep 26;92(20). pii: e01089-18. doi: 10.1128/JVI.01089-18. Print 2018 Oct 15.

5.

DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination.

Hu X, Valentin A, Cai Y, Dayton F, Rosati M, Ramírez-Salazar EG, Kulkarni V, Broderick KE, Sardesai NY, Wyatt LS, Earl PL, Moss B, Mullins JI, Pavlakis GN, Felber BK.

Hum Gene Ther. 2018 Sep;29(9):1029-1043. doi: 10.1089/hum.2018.065. Epub 2018 Jun 21.

6.

Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles.

Liu B, Panda D, Mendez-Rios JD, Ganesan S, Wyatt LS, Moss B.

J Virol. 2018 Mar 14;92(7). pii: e02152-17. doi: 10.1128/JVI.02152-17. Print 2018 Apr 1.

7.

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.

Jones AT, Chamcha V, Kesavardhana S, Shen X, Beaumont D, Das R, Wyatt LS, LaBranche CC, Stanfield-Oakley S, Ferrari G, Montefiori DC, Moss B, Tomaras GD, Varadarajan R, Amara RR.

J Virol. 2018 Feb 12;92(5). pii: e01796-17. doi: 10.1128/JVI.01796-17. Print 2018 Mar 1.

8.

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.

Shen X, Basu R, Sawant S, Beaumont D, Kwa SF, LaBranche C, Seaton KE, Yates NL, Montefiori DC, Ferrari G, Wyatt LS, Moss B, Alam SM, Haynes BF, Tomaras GD, Robinson HL.

J Virol. 2017 Nov 30;91(24). pii: e01077-17. doi: 10.1128/JVI.01077-17. Print 2017 Dec 15.

9.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Protein Sci. 2017 Aug 1;89:5.12.1-5.12.18. doi: 10.1002/cpps.34.

PMID:
28762495
10.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Protein Sci. 2017 Aug 1;89:5.13.1-5.13.18. doi: 10.1002/cpps.33.

11.

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins.

Wyatt LS, Xiao W, Americo JL, Earl PL, Moss B.

MBio. 2017 Jun 6;8(3). pii: e00790-17. doi: 10.1128/mBio.00790-17.

12.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Mol Biol. 2017 Jan 5;117:16.16.1-16.16.18. doi: 10.1002/cpmb.33.

PMID:
28060410
13.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Mol Biol. 2017 Jan 5;117:16.17.1-16.17.18. doi: 10.1002/cpmb.32.

PMID:
28060405
14.

High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.

Kannanganat S, Wyatt LS, Gangadhara S, Chamcha V, Chea LS, Kozlowski PA, LaBranche CC, Chennareddi L, Lawson B, Reddy PB, Styles TM, Vanderford TH, Montefiori DC, Moss B, Robinson HL, Amara RR.

J Immunol. 2016 Nov 1;197(9):3586-3596. Epub 2016 Sep 28.

15.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Microbiol. 2015 Nov 3;39:14A.4.1-18. doi: 10.1002/9780471729259.mc14a04s39.

16.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Microbiol. 2015 Nov 3;39:14A.3.1-18. doi: 10.1002/9780471729259.mc14a03s39.

17.

Poxvirus decapping enzymes enhance virulence by preventing the accumulation of dsRNA and the induction of innate antiviral responses.

Liu SW, Katsafanas GC, Liu R, Wyatt LS, Moss B.

Cell Host Microbe. 2015 Mar 11;17(3):320-331. doi: 10.1016/j.chom.2015.02.002.

18.

The D10 decapping enzyme of vaccinia virus contributes to decay of cellular and viral mRNAs and to virulence in mice.

Liu SW, Wyatt LS, Orandle MS, Minai M, Moss B.

J Virol. 2014 Jan;88(1):202-11. doi: 10.1128/JVI.02426-13. Epub 2013 Oct 23.

19.

Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

Melamed S, Wyatt LS, Kastenmayer RJ, Moss B.

Vaccine. 2013 Sep 23;31(41):4569-77. doi: 10.1016/j.vaccine.2013.07.057. Epub 2013 Aug 6.

20.

Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.

Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gomez CE, Esteban M, Wyatt LS, Moss B, Morgan C, Roederer M, Bailer RT, Nabel GJ, Koup RA, Seder RA.

J Immunol. 2013 Mar 15;190(6):2720-35. doi: 10.4049/jimmunol.1202861. Epub 2013 Feb 6.

21.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31.

22.

The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

Shinoda K, Wyatt LS, Moss B.

Virology. 2010 Sep 15;405(1):41-9. doi: 10.1016/j.virol.2010.05.025. Epub 2010 Jun 17.

23.

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection.

Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, Vogt J, Moss B.

J Virol. 2009 Jul;83(14):7176-84. doi: 10.1128/JVI.00687-09. Epub 2009 May 6.

24.

Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Shinoda K, Wyatt LS, Irvine KR, Moss B.

Virol J. 2009 Mar 3;6:28. doi: 10.1186/1743-422X-6-28.

25.

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

Zhao J, Lai L, Amara RR, Montefiori DC, Villinger F, Chennareddi L, Wyatt LS, Moss B, Robinson HL.

J Virol. 2009 May;83(9):4102-11. doi: 10.1128/JVI.02173-08. Epub 2009 Feb 18.

26.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L Jr, Spano YE, Silvera PM, Moss B.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.

27.

Generation of recombinant vaccinia viruses.

Earl PL, Moss B, Wyatt LS, Carroll MW.

Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.13. doi: 10.1002/0471140864.ps0513s13.

PMID:
18429179
28.

Preparation of cell cultures and vaccinia virus stocks.

Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW.

Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.12. doi: 10.1002/0471140864.ps0512s13.

29.

A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture.

Senkevich TG, Wyatt LS, Weisberg AS, Koonin EV, Moss B.

Virology. 2008 May 10;374(2):506-14. doi: 10.1016/j.virol.2008.01.009. Epub 2008 Feb 20.

30.

Generation of recombinant vaccinia viruses.

Earl PL, Moss B, Wyatt LS, Carroll MW.

Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.17. doi: 10.1002/0471142727.mb1617s43.

PMID:
18265124
31.

Preparation of cell cultures and vaccinia virus stocks.

Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW.

Curr Protoc Mol Biol. 2001 May;Chapter 16:Unit16.16. doi: 10.1002/0471142727.mb1616s43.

PMID:
18265123
32.

Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.

Robinson HL, Sharma S, Zhao J, Kannanganat S, Lai L, Chennareddi L, Yu T, Montefiori DC, Amara RR, Wyatt LS, Moss B.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1555-62.

PMID:
18160013
33.

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Wyatt LS, Earl PL, Vogt J, Eller LA, Chandran D, Liu J, Robinson HL, Moss B.

Vaccine. 2008 Jan 24;26(4):486-93. Epub 2007 Dec 3.

34.
35.

Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.

Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, Molina DM, Hirst S, Moss B, Frey SE, Felgner PL.

J Virol. 2008 Jan;82(2):652-63. Epub 2007 Oct 31.

36.

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.

Lai L, Vödrös D, Kozlowski PA, Montefiori DC, Wilson RL, Akerstrom VL, Chennareddi L, Yu T, Kannanganat S, Ofielu L, Villinger F, Wyatt LS, Moss B, Amara RR, Robinson HL.

Virology. 2007 Dec 5;369(1):153-67. Epub 2007 Aug 14.

37.

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.

Nigam P, Earl PL, Americo JL, Sharma S, Wyatt LS, Edghill-Spano Y, Chennareddi LS, Silvera P, Moss B, Robinson HL, Amara RR.

Virology. 2007 Sep 15;366(1):73-83. Epub 2007 May 16.

38.

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.

Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, Byrum R, Piatak M, Lifson JD, Amara RR, Robinson HL, Huggins JW, Moss B.

Virology. 2007 Sep 15;366(1):84-97. Epub 2007 May 11.

39.

Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost.

Liu J, Hellerstein M, McDonnel M, Amara RR, Wyatt LS, Moss B, Robinson HL.

Vaccine. 2007 Apr 12;25(15):2951-8. Epub 2006 Jun 9.

PMID:
17360078
40.

T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells.

de Waal L, Süzer Y, Wyatt LS, Sintnicolaas K, Sutter G, Moss B, Osterhaus AD, de Swart RL.

Viral Immunol. 2006 Winter;19(4):669-78.

PMID:
17201662
41.

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine.

Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR.

Virology. 2006 Sep 1;352(2):285-94. Epub 2006 Jun 5.

42.

Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.

Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL.

Vaccine. 2006 Apr 12;24(16):3332-9. Epub 2006 Jan 19.

PMID:
16472543
43.
44.

Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses.

Smith JM, Amara RR, Wyatt LS, Ellenberger DL, Li B, Herndon JG, Patel M, Sharma S, Chennareddi L, Butera S, McNicholl J, McClure HM, Moss B, Robinson HL.

AIDS Res Hum Retroviruses. 2005 Feb;21(2):140-4.

PMID:
15725752
45.

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.

Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, Butera ST, Ellenberger DL, Yi H, Chennareddi L, Herndon JG, Wyatt LS, Montefiori D, Moss B, McClure HM, Robinson HL.

AIDS Res Hum Retroviruses. 2004 Dec;20(12):1335-47.

PMID:
15650426
46.

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.

Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, Robinson HL.

AIDS Res Hum Retroviruses. 2004 Jun;20(6):654-65.

PMID:
15242543
47.

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.

Wyatt LS, Earl PL, Liu JY, Smith JM, Montefiori DC, Robinson HL, Moss B.

AIDS Res Hum Retroviruses. 2004 Jun;20(6):645-53.

PMID:
15242542
48.

Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.

de Waal L, Wyatt LS, Yüksel S, van Amerongen G, Moss B, Niesters HG, Osterhaus AD, de Swart RL.

Vaccine. 2004 Feb 25;22(8):923-6.

PMID:
15161069
49.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Wyatt LS, Earl PL, Eller LA, Moss B.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. Epub 2004 Mar 11.

50.

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.

Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B.

Nature. 2004 Mar 11;428(6979):182-5.

PMID:
15014500

Supplemental Content

Loading ...
Support Center